MedTrace Logo

Long-Term Follow-up Study for Subjects With CHB Previously Treated With Imdusiran (AB729)

NCT06277037 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 50

Last updated 2024-11-27

No results posted yet for this study

Summary

This is a long term follow-up study for chronic hepatitis B (CHB) subjects who have received imdusiran treatment in a prior clinical trial, stopped NA therapy during that trial, and remain off therapy. Subjects may enroll after completing the end of study visit (baseline visit within 12 weeks ± 1 week from the end of study \[EOS\] visit) from their imdusiran clinical trial (the "parent study"). No interventions will be performed in this study other than blood sample collections, review of current medications, and reporting of any adverse events related to study procedures or NA therapy if restarted. Study participation will be for approximately 2 years (to complete a total of at least 3 years of follow-up while off NA therapy, inclusive of parent study participation).

Conditions

  • Long Term Follow-up

Interventions

OTHER

Non-interventional

This is a rollover study

Sponsors & Collaborators

  • Arbutus Biopharma Corporation

    lead INDUSTRY

Eligibility

Min Age
20 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-07-11
Primary Completion
2029-08-30
Completion
2029-10-30

Countries

  • United States
  • Australia
  • Hong Kong
  • Moldova
  • South Korea
  • Taiwan
  • United Kingdom

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06277037 on ClinicalTrials.gov